Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Report First Quarter Results on May 13, 2024

Tuesday, May 7, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. will report its first quarter results on May 13, 2024. The company is known for its innovative gene editing technologies, particularly its proprietary ARCUS platform. This platform is designed for in vivo gene editing therapies, enabling complex gene modifications such as elimination, insertion, and excision.
Price reaction · baseline $10.57 (2024-05-07 close) · hit after-hours · 3 other DTIL headline(s) in the window, move may be shared
day 0 close
+6.6%
day 1
+3.4%
day 3 · peak
+8.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technology.
  • The company is utilizing its proprietary ARCUS platform.
  • The upcoming report may provide insights into their progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 7, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision,

Frequently Asked Questions

When will Precision BioSciences report its Q1 results?

Precision BioSciences will report its first quarter results on May 13, 2024.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing.

What types of gene edits can ARCUS perform?

ARCUS can perform gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform Q1 results
Last updated: May 7, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →